Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316

NCT02041221 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: SPARC1316 Dose 1
DRUG: Placebo
DRUG: SPARC1316 Dose 2
DRUG: SPARC1316 Dose 3
DRUG: SPARC1316 Dose 4
DRUG: SPARC1316 Dose 5

Sponsor

Sun Pharma Advanced Research Company Limited